Metabolomic and elemental profiling of blood serum in bladder cancer

September 2022

Authors: MD, FEBU Anna Ossolińska, MD, PhD, FEBU Tadeusz Ossolinski, MD, PhD, FEBU Krzysztof Ossoliński, Tomasz Ruman 2, Valérie Copié 3, Brian P Tripet 3, Leonardo B Nogueira 4, Katiane O P C Nogueira 5, Artur Kołodziej 6, Aneta Płaza-Altamer 6, ,Joanna Nizioł 2

Abstract

This study performed both targeted and untargeted profiling of metabolites and elements in human blood serum from 100 bladder cancer patients and 100 normal controls. Three analytical platforms were used: ^1H NMR, nanoparticle-based LDI-MS (gold and silver-109), and ICP-OES, followed by multivariate statistical analysis. Four serum biomarkers—isobutyrate, pyroglutamate, choline and acetate—were quantified by NMR with excellent predictive AUC = 0.999. Two elements, Li and Fe, distinguished cancer from control with AUC = 0.807. Twenty-five additional compounds (mainly glycans/lipids) differentiated BC from controls via LDI‑MS. Several metabolites correlated significantly with tumor grade and stage. The combined use of three platforms suggests potential for non‑invasive detection, staging, and grading of bladder cancer.

Full link below:

Metabolomic and elemental profiling of blood serum in bladder cancer – PubMed